By: Amrita Singh, PharmD Candidate c/o 2015 – Last November, the American College of Cardiology and the American Heart Association released new lipid guidelines, which will transform the way we manage our patients with hyperlipidemia. Earlier, lipid management was based on the ATP-III guidelines, which emphasized the use of several lipid-lowering medications to reach target…

By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol.  Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus…

By: Yufan (Frank) Liu, Pharm.D. Candidate c/o 2013 – Results of numerous epidemiological studies have indicated that having high serum cholesterol can lead to coronary heart disease (CHD). 1 More specifically having high LDL cholesterol puts patients at risk for angina and heart attack.2 To reduce this risk HMG-CoA reductase inhibitors, also known as statins,…

By: Mohamed Dungersi – On February 28, the U.S. Food and Drug Administration (FDA) approved important safety label changes for the class of cholesterol-lowering drugs known as statins.  Aligned with the FDA’s goal to provide the public with more information for the safe and effective use of statins, the agency made several modifications to the…